Cited by 279Viral Infections and Immunology ResearchTakotsubo Cardiomyopathy and Associated PhenomenaStreptococcal Infections and Treatments

Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction

Open access
Ammirati, Enrico, Veronese, Giacomo, Brambatti, Michela, Merlo, Marco, Cipriani, Manlio, Potena, Luciano, Sormani, Paola, Aoki, Tatsuo +38 more·2019·Journal of the American College of Cardiology

Abstract

Background Fulminant myocarditis (FM) is a form of acute myocarditis characterized by severe left ventricular systolic dysfunction requiring inotropes and/or mechanical circulatory support. A single-center study found that a patient with FM had better outcomes than those with acute nonfulminant myocarditis (NFM) presenting with left ventricular systolic dysfunction, but otherwise hemodynamically stable. This was recently challenged, so disagreement still exists. Objectives This study sought to provide additional evidence on the outcome of FM and to ascertain whether patient stratification based on the main histologic subtypes can provide additional prognostic information. Methods A total of 220 patients (median age 42 years, 46.3% female) with histologically proven acute myocarditis (onset of symptoms <30 days) all presenting with left ventricular systolic dysfunction were included in a retrospective, international registry comprising 16 tertiary hospitals in the United States, Europe, and Japan. The main endpoint was the occurrence of cardiac death or heart transplantation within 60 days from admission and at long-term follow-up. Results Patients with FM (n = 165) had significantly higher rates of cardiac death and heart transplantation compared with those with NFM (n = 55), both at 60 days (28.0% vs. 1.8%, p = 0.0001) and at 7-year follow-up (47.7% vs. 10.4%, p < 0.0001). Using Cox multivariate analysis, the histologic subtype emerged as a further variable affecting the outcome in FM patients, with giant cell myocarditis having a significantly worse prognosis compared with eosinophilic and lymphocytic myocarditis. In a subanalysis including only adults with lymphocytic myocarditis, the main endpoints occurred more frequently in FM compared with in NFM both at 60 days (19.5% vs. 0%, p = 0.005) and at 7-year follow up (41.4% vs. 3.1%, p = 0.0004). Conclusions This international registry confirms that patients with FM have higher rates of cardiac death and heart transplantation both in the short- and long-term compared with patients with NFM. Furthermore, we provide evidence that the histologic subtype of FM carries independent prognostic value, highlighting the need for timely endomyocardial biopsy in this condition.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2019.04.063

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Lymphocytic myocarditis is characterized by myocardial infiltrates with T lymphocytes and macrophages.

    “Lymphocytic myocarditis is characterized by myocardial infiltrates with T lymphocytes and macrophages.”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [198]

    The Abstract describes myocarditis as an inflammatory disease of the myocardium with inflammatory infiltrates, and the Methods identify lymphocytic myocarditis as a histologic subtype. Our copy does not specify that those infiltrates contain T lymphocytes and macrophages, so the cellular characterization is unsupported. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Various conditions including infections, drugs, hypersensitivity, and autoimmune factors may be associated with the onset and progress of eosinophilic myocarditis.

    “various conditions including infections, drugs, hypersensitivity, and autoimmune factors may be associated with the onset and progress of this disease.”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [198]

    The introductory passage (indexed under Abstract; page not provided) lists infection, autoimmune disorders, hypersensitivity reactions, and drugs as potential causes of myocarditis generally. Table 5 and its accompanying text report autoimmune disorders among patients with eosinophilic myocarditis. The copy does not establish that all four factors are associated specifically with the onset or progression of eosinophilic myocarditis. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 29

  1. Cooper LT Jr. Myocarditis. N Engl J Med 2009; 360:1526-38.
  2. Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E. Eosinophilic myocarditis: characteristics, treatment, and outcomes. J Am Coll Cardiol 2017;70:2363-75.
  3. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375: 1749-55.
  4. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018;71: 1755-64.
  5. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the man- agement of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the Eu- ropean Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 2007;50:1914-31.
  6. Chow LH, Radio SJ, Sears TD, McManus BM. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol 1989;14:915-20.
  7. Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol 1987;18:619-24.
  8. Trachtenberg BH, Hare JM. Inflammatory car- diomyopathic syndromes. Circ Res 2017;121: 803-18.
  9. Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation 2006;113:593-5.
  10. Ammirati E, Cipriani M, Moro C, et al., for the Registro Lombardo delle Miocarditi. Clinical pre- sentation and outcome in a contemporary cohort of patients with acute myocarditis. Circulation 2018;138:1088-99.
  11. Caforio AL, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopatho- genetic features at diagnosis. Eur Heart J 2007; 28:1326-33.
  12. Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008;118:639-48.
  13. McCarthy RE 3rd., Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocar- ditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000;342:690-5.
  14. Ginsberg F, Parrillo JE. Fulminant myocarditis. Critic Care Clin 2013;29:465-83.
  15. Ammirati E, Cipriani M, Lilliu M, et al. Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis. Circulation 2017;136:529-45.
  16. Cooper LT Jr. When lightning strikes: fulmi- nant myocarditis in the realm of inflammatory cardiomyopathies. Circulation 2017;136:546-8.
  17. Ammirati E, Veronese G, Cipriani M, et al. Acute and fulminant myocarditis: a pragmatic clinical approach to diagnosis and treatment. Curr Cardiol Rep 2018;20:114.
  18. Singh V, Mendirichaga R, Savani GT, et al. Comparison of utilization trends, indications, and complications of endomyocardial biopsy in native versus donor hearts (from the Nationwide Inpa- tient Sample 2002 to 2014). Am J Cardiol 2018; 121:356-63.
  19. Cooper LT Jr., Hare JM, Tazelaar HD, et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008;102:1535-9.
  20. Kandolin R, Lehtonen J, Salmenkivi K, Raisa- nen-Sokolowski A, Lommi J, Kupari M. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail 2013;6:15-22.
  21. Cooper LT Jr., Berry GJ, Shabetai R. Multicenter Giant Cell Myocarditis Study Group Investigators. Idiopathic giant-cell myocarditis- natural history and treatment. N Engl J Med 1997; 336:1860-6.
  22. Mason JW, O'Connell JB, Herskowitz A, et al., for the Myocarditis Treatment Trial Investigators. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995;333:269-75.
  23. Asaumi Y, Yasuda S, Morii I, et al. Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygena- tion. Eur Heart J 2005;26:2185-92.
  24. Magnani JW, Danik HJ, Dec GW Jr., DiSalvo TG. Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. Am Heart J 2006;151:463-70.
  25. Montero S, Aissaoui N, Tadié J-M, et al. Fulminant giant-cell myocarditis on mechanical circulatory support: management and outcomes of a French multicentre cohort. Int J Cardiol 2018; 253:105-12.
  26. Ekstrom K, Lehtonen J, Kandolin R, Raisanen- Sokolowski A, Salmenkivi K, Kupari M. Long-term outcome and its predictors in giant cell myocar- ditis. Eur J Heart Fail 2016;18:1452-8.
  27. Ukena C, Mahfoud F, Kindermann I, Kandolf R, Kindermann M, Bohm M. Prognostic electrocardiographic parameters in patients with suspected myocarditis. Eur J Heart Fail 2011;13: 398-405.
  28. Sawamura A, Okumura T, Ito M, et al., for the CHANGE PUMP Investigators. Prognostic value of electrocardiography in patients with fulminant myocarditis supported by percutaneous venoar- terial extracorporeal membrane oxygenation: analysis from the CHANGE PUMP Study. Circ J 2018;82:2089-95.
  29. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflamma- tory cardiomyopathy: the TIMIC study. Eur Heart J 2009;30:1995-2002.

Cited by

Sorted by citations

Authors
Ammirati, E., Veronese, G., Brambatti, M., Merlo, M., Cipriani, M., Potena, L., Sormani, P., Aoki, T., Sugimura, K., Sawamura, A., Okumura, T., Pinney, S., Hong, K., Shah, P., Braun, Ö., Van de Heyning, C. M., Montero, S., Petrella, D., Huang, F., Schmidt, M., Raineri, C., Lala, A., Varrenti, M., Foà, A., Leone, O., Gentile, P., Artico, J., Agostini, V., Patel, R., Garascia, A., Van Craenenbroeck, E. M., Hirose, K., Isotani, A., Murohara, T., Arita, Y., Sionis, A., Fabris, E., Hashem, S., Garcia-Hernando, V., Oliva, F., Greenberg, B., Shimokawa, H., Sinagra, G., Adler, E. D., Frigerio, M., & Camici, P. G.
Affiliations
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
  • University of California San Diego (US)
  • University of Trieste (IT)
  • IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
  • Tohoku University (JP)
  • Nagoya University (JP)
  • Icahn School of Medicine at Mount Sinai (US)
  • Inova Health System (US)
  • Universitat Autònoma de Barcelona (ES)
  • Sorbonne Université (FR)
  • Kokura Memorial Hospital (JP)
  • Osaka Hospital (JP)
  • Vita-Salute San Raffaele University (IT)
Corresponding author
Ammirati, Enrico
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2019-07
Volume
74
Issue
3
Pages
299-311
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2959591820
Cited by
279
References
1
Citations by year
2026: 41 · 2025: 52 · 2024: 38 · 2023: 40 · 2022: 49 · 2021: 23 · 2020: 29 · 2019: 7
FWCI
19.52
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Viral Infections and Immunology Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Takotsubo Cardiomyopathy and Associated Phenomena
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Streptococcal Infections and Treatments
Keywords
fulminant myocarditis, left ventricular systolic dysfunction, giant cell myocarditis, eosinophilic myocarditis, lymphocytic myocarditis, histological subtypes, cardiovascular mortality, heart transplantation, prognosis, endomyocardial biopsy, mechanical circulatory support, inotropic agents, long-term outcomes
MeSH terms
Acute Disease, Adult, Female, Humans, Male, Middle Aged, Myocarditis, Prognosis, Retrospective Studies, Severity of Illness Index, Ventricular Dysfunction, Left

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review